Bisphosphonate INCADRONATE (cas 138330-18-4) prevents total gastrectomy-induced osteopenia in rats
-
Add time:08/24/2019 Source:sciencedirect.com
Purpose. Total gastrectomy (GX) leads to osteopenia. We examined the effects of bisphosphonate INCADRONATE (cas 138330-18-4) (INC), a potent inhibitor of bone resorption, on bone characteristics in rats that underwent total GX. Experimental design. Male Wistar rats were divided into four groups: (1) sham-operation (n = 10); (2) total GX control (n = 6); (3) total GX with 0.3 mg kg−1 day−1 oral administration of INC (n = 7); and (4) total GX with 3.0 mg kg−1 day−1 oral administration of INC (n = 7). Results. Total GX significantly impaired bone mineral density; these effects were prevented by treatment with INC. Similarly, in GX control rats, morphometrical changes of femoral metaphysis stained with Villanueva's and Villanueva-Goldner's: bone volume, tissue volume, mineral apposition rate, labeled/bone surface, bone formation rate, osteoid volume, mineralization lag time as well as serum osteocalcin, and urinary deoxypyridinoline demonstrated simultaneous existence of both osteomalacia and osteopenia; these impairments were also prevented by INC. However, GX-induced decrease in serum levels of calcium as well as 25-hydroxyvitamin D/24,25-dihydroxyvitamin D and the increase in 1,25-dihydroxyvitamin D were not prevented by administration of INC. Conclusions. These results enhance the understanding of the unique pathophysiology of both osteomalacia and osteoporosis induced by total GX and suggest the possibility of using INC as preventive therapy for osteopenia in GX-treated patients.
We also recommend Trading Suppliers and Manufacturers of INCADRONATE (cas 138330-18-4). Pls Click Website Link as below: cas 138330-18-4 suppliers
Prev:Comparison of INCADRONATE (cas 138330-18-4) and alfacalcidol on increased bone turnover caused by ovariectomy in rats
Next:Evaluation of long-term sequential changes in bone mass and strength following withdrawal of INCADRONATE (cas 138330-18-4) disodium (YM175) in ovariectomized rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Evaluation of long-term sequential changes in bone mass and strength following withdrawal of INCADRONATE (cas 138330-18-4) disodium (YM175) in ovariectomized rats08/25/2019
- Comparison of INCADRONATE (cas 138330-18-4) and alfacalcidol on increased bone turnover caused by ovariectomy in rats08/23/2019
- From Lab to ClinicLack of Prophylactic Effect of INCADRONATE (cas 138330-18-4) on Skeletal Lesions Associated with Implants of Prostate Cancer☆08/22/2019
- INCADRONATE (cas 138330-18-4) inhibits osteoporosis in ovariectomized rats08/21/2019
- INCADRONATE (cas 138330-18-4) inhibits aminopeptidase N expression in prostatic PC-3 cells08/20/2019
- INCADRONATE (cas 138330-18-4) disodium inhibits advanced glycation end products-induced angiogenesis in vitro☆08/19/2019


